Skip to main content
Data Highlights Editorials
All dashboards COVID Symptom Study Sweden (Partner) COVID-19 publication overview CRUSH Covid Uppsala (Partner) Multi-disease serology Post COVID-19 condition Register-based vaccination (RECOVAC) SARS-CoV-2 tests at National Pandemic Centre SARS-CoV-2 variant competition SARS-CoV-2 whole genome sequencing (Region Uppsala) Serology tests for SARS-CoV-2 at SciLifeLab Vaccine administration: COVID-19 Wastewater: Enteric Virus Quantification (GU) Wastewater: Influenza Quantification (SLU) Wastewater: RSV Quantification (SLU) Wastewater: SARS-CoV-2 Quantification
Share data Available datasets Data dashboards Data sources & repositories Sample collection database Research data management
Funding opportunities Ongoing research projects Register-based research Swedish COVID-19 Publications
Emerging Pathogens SciLifeLab PLP PLP Capabilities
All topics Antibiotic resistance COVID-19 Enteric viruses Infectious diseases Influenza Mpox Respiratory Syncytial Virus (RSV)

State-of-the-art biosafety level 3 (BSL3) facility

State-of-the-art biosafety level 3 (BSL3) facility


Funding given for project project entitled:

BSL3 Biomedicum-SciLifeLab Collaborative Platform

PI(s)/Head responsible for the resource:

Antonio Rothfuchs, Marianna Tampere

Host organisation(s):

Karolinska Institutet

Resource description:

BSL3 Biomedicum is fully equipped with state-of-the-art equipment and expertise staff to perform a wide range of research with any BSL3 pathogens. Our facility offers unique applications for pathogen aerobiology and high-throughput screening and service-based projects for external users.

BSL3 Biomedicum is open for companies to perform their research with pathogenic viruses. As an example, Biomedrex is developing CRISPR-based antivirals at BSL3 Biomedicum.

For more information on the Pandemic Laboratory Preparedness resources associated with this subproject, see BSL3 Biomedicum-SciLifeLab Collaborative Platform and Swedish biosafety level 3 (BSL3) network.

A generic square placeholder image with rounded corners in a figure.
An example of high-throughput antiviral assays available at BSL3 Biomedicum. An image-based screening assay was developed in collaboration with Dr. Charlotte Stadler (Kaimal et al. bioRxiv, 2022) and cell viability assay in collaboration with Dr. Marianna Tampere.
A generic square placeholder image with rounded corners in a figure.
Testing CRISPR-based antivirals at BSL3 Biomedicum.
How this resource can be used for Pandemic Preparedness research:

A lot of pandemic preparedness research requires a dedicated facility to handle pathogens in a safe environment. BSL3 Biomedicum offers both a safe environment for pathogen handling as well as expertise for research projects.

Who and under which conditions is able to access the resource:

Access to the BSL-3 facility is preceded by the fulfillment of entry requirements which encompass understanding the risks associated with the handling of the pathogens used in the facility and understanding how to perform experiments with the same in an orderly and safe manner. As a service the facility provides training to new users and experimental support. Enquiries about access to the facility should be made well in advance so that risk assessments, permits, procedures and training needs can be addressed. To enquire access to the facility, please fill in the project request form and send it to bsl3biomedicum@ki.se.

Webpage:

ki.se/en/research/the-biosafety-level-3-laboratory-bsl3-at-biomedicum

Contact information:

Antonio Gigliotti Rothfuchs
BSL3 Director
Email: antonio.rothfuchs@ki.se